Market revenue in 2023 | USD 140.2 million |
Market revenue in 2030 | USD 345.0 million |
Growth rate | 13.7% (CAGR from 2023 to 2030) |
Largest segment | Ctms |
Fastest growing segment | ECOA |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | ECOA, EDC & CDMS, Clinical Analytics Platforms, Clinical Data Integration Platforms, Safety solutions, CTMS, RTSM, ETMF, EConsent |
Key market players worldwide | DATATRAK International Inc, Oracle Corp, PAREXEL, Dassault Systemes SE, Signant Health, Clario, eClinicalWorks, International Business Machines Corp, IQVIA Holdings Inc, Veeva Systems Inc Class A, Anju Software, MaxisIT Inc., Castor |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to eclinical solutions market will help companies and investors design strategic landscapes.
Ctms was the largest segment with a revenue share of 20.19% in 2023. Horizon Databook has segmented the Taiwan eclinical solutions market based on ecoa, edc & cdms, clinical analytics platforms, clinical data integration platforms, safety solutions, ctms, rtsm, etmf, econsent covering the revenue growth of each sub-segment from 2018 to 2030.
Taiwan is believed to be one of the emerging destinations for clinical trials considering costeffectiveness, economic sustainability and capability to conduct early stage clinical trials. According to ClinicalTrials.gov, it was reported that 630 open Phase I studies were conducted in Taiwan. Increasing number of collaborative agreements is anticipated to increase this number further over the coming years.
For instance, Taiwan has entered into a collaborative agreement with China to develop biotechnology industry and development of therapeutically advanced drugs. The aforementioned factors cumulatively exert a positive impact on the growth across this country. Furthermore, rising number of academic collaborations is presumed to heighten the adoption rate of eClinical solutions in Taiwan.
For instance, in November 2012, PARAXEL and National Taiwan University Hospital entered into partnership to enhance clinical research as well as drug development services in Taiwan.
Horizon Databook provides a detailed overview of country-level data and insights on the Taiwan eclinical solutions market , including forecasts for subscribers. This country databook contains high-level insights into Taiwan eclinical solutions market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account